secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2023-06-30T23:59:59+00:00
Accession:  0001104659-23-077061
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics raises ~$71.6M in public offering of 15M shares at $5.00/share
--------------------------------------------------------------------------------

- Underwritten public offering of 15,000,000 shares at $5.00/share; net proceeds ~$71.6M.
- Underwriters have 30-day option to buy up to 2,250,000 additional shares (full exercise net ~$82.4M).
- Proceeds to advance clinical pipeline including BDTX-1535 for non-small cell lung cancer and for working capital.
- Underwriting agreement with Piper Sandler & Co.; officers/directors subject to 60-day lock-up.
- Offering expected to close July 5, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465923077061/0001104659-23-077061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465923077061/tm2320300d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-077061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer